Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy.
OBJECTIVE
To investigate the relation of the response to Helicobacter pylori eradication therapy to the depth of tumor invasion and chromosome abnormalities in patients with mucosa-associated lymphoid tissue (MALT) lymphoma and to determine the clinical value of aneuploidy.


METHODS
We studied 13 patients with localized gastric MALT lymphoma of stage E1. Before eradication therapy, the depth of tumor invasion was assessed by endoscopic ultrasonography in 8 patients and by endoscopic examination and gastrointestinal series in the remaining patients. To detect chromosomal abnormalities, paraffin-embedded tissue sections of diagnostic biopsy specimens underwent tissue-fluorescence in situ hybridization (FISH), using chromosome-specific alpha-satellite DNA probes for chromosomes 3,7,12, and 18 and YAC clones for t(11;18)(q21;q21).


RESULTS
Seven of the 13 patients had complete regression (CR) in response to H pylori eradication therapy. No patient with CR had submucosal tumor invasion. Trisomy 18 was seen in 1 patient with CR, and both trisomies 12 and 18 were present in another patient with CR. All patients with no response or progressive disease had deep submucosal tumor invasion and showed t(11;18)(q21;q21) or trisomy 3. Trisomy 7 was not detected in this series of patients.


CONCLUSIONS
The depth of tumor invasion is an accurate predictor of the response of stage E1 MALT lymphoma to H pylori eradication therapy and is closely associated with the presence of chromosomal abnormalities. Trisomy 3 may predict the aggressive development of MALT lymphoma.
Taji
Sawako
S
Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Nomura
Kenichi
K
Matsumoto
Yosuke
Y
Sakabe
Hideaki
H
Yoshida
Naohisa
N
Mitsufuji
Shoji
S
Nishida
Kazuhiro
K
Horiike
Shigeo
S
Nakamura
Shigeo
S
Morita
Masuji
M
Taniwaki
Masafumi
M
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002880:Chromosomes, Human, Pair 11; D002887:Chromosomes, Human, Pair 18; D002893:Chromosomes, Human, Pair 3; D005260:Female; D005500:Follow-Up Studies; D005820:Genetic Testing; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D018442:Lymphoma, B-Cell, Marginal Zone / Q000235:genetics* / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D013274:Stomach Neoplasms / Q000235:genetics* / Q000382:microbiology / Q000473:pathology; D014314:Trisomy
D000900:Anti-Bacterial Agents